Sjogren's Syndrome (SS)
6
3
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
MTS109 in Patients With Refractory Autoimmune Diseases
A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)